Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge

Research output: Contribution to journalReview article

Abstract

Gastroenteropancreatic neuroendocrine tumors (NETs) are a relatively rare group of heterogeneous neoplasms. The most significant advance in therapy of NETs has been the advent of the somatostatin analog octreotide, which represents a cornerstone in their management and dramatically changed the therapeutic landscape. Octreotide long-acting release (LAR) was developed to overcome some of the limitations of octreotide. Several clinical studies, including PROMID and RADIANT-2, have validated the clinical benefits of octreotide LAR in NETs, with tumor shrinkage in about 10% of patients and tumor stabilization in roughly half of cases. While the use of octreotide LAR is well-consolidated in NETs, some open questions remain. These include the use of high-dose octreotide LAR, as there is evidence that higher dose may provide longer disease control, and nonstandard treatment schedules, with administration every 21 days instead of 28 days, as well as their use in combination with targeted agents or peptide receptor radiotherapy in clinical practice. After 3 decades of clinical experience with octreotide LAR, the drug has a well-established safety profile. It is well-tolerated and treatment discontinuations due to adverse events are uncommon. One exception is cholelithiasis, which may increase with longer duration of treatment. According to the literature data, octreotide LAR is currently recommended in both functioning and nonfunctioning advanced NETs. This review summarizes the available clinical data with octreotide LAR and also provides future perspectives on its possible uses in patients with NETs.

Original languageEnglish
Pages (from-to)113-120
Number of pages8
JournalTumori
Volume105
Issue number2
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Octreotide
Neuroendocrine Tumors
Therapeutics
Neoplasms
Cholelithiasis
Peptide Receptors
Somatostatin
Appointments and Schedules
Radiotherapy
Safety

Keywords

  • carcinoid tumors
  • Gastroenteropancreatic neuroendocrine tumors
  • octreotide LAR
  • somatostatin analogs
  • therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{3841789f5d4341de891ce1dada45c5fb,
title = "Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge",
abstract = "Gastroenteropancreatic neuroendocrine tumors (NETs) are a relatively rare group of heterogeneous neoplasms. The most significant advance in therapy of NETs has been the advent of the somatostatin analog octreotide, which represents a cornerstone in their management and dramatically changed the therapeutic landscape. Octreotide long-acting release (LAR) was developed to overcome some of the limitations of octreotide. Several clinical studies, including PROMID and RADIANT-2, have validated the clinical benefits of octreotide LAR in NETs, with tumor shrinkage in about 10{\%} of patients and tumor stabilization in roughly half of cases. While the use of octreotide LAR is well-consolidated in NETs, some open questions remain. These include the use of high-dose octreotide LAR, as there is evidence that higher dose may provide longer disease control, and nonstandard treatment schedules, with administration every 21 days instead of 28 days, as well as their use in combination with targeted agents or peptide receptor radiotherapy in clinical practice. After 3 decades of clinical experience with octreotide LAR, the drug has a well-established safety profile. It is well-tolerated and treatment discontinuations due to adverse events are uncommon. One exception is cholelithiasis, which may increase with longer duration of treatment. According to the literature data, octreotide LAR is currently recommended in both functioning and nonfunctioning advanced NETs. This review summarizes the available clinical data with octreotide LAR and also provides future perspectives on its possible uses in patients with NETs.",
keywords = "carcinoid tumors, Gastroenteropancreatic neuroendocrine tumors, octreotide LAR, somatostatin analogs, therapy",
author = "Sara Pusceddu and Natalie Prinzi and Alessandra Raimondi and Francesca Corti and Roberto Buzzoni and {Di Bartolomeo}, Maria and Ettore Seregni and Marco Maccauro and Jorgelina Coppa and Massimo Milione and Vincenzo Mazzaferro and {de Braud}, Filippo",
year = "2019",
month = "4",
day = "1",
doi = "10.1177/0300891618765362",
language = "English",
volume = "105",
pages = "113--120",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Entering the third decade of experience with octreotide LAR in neuroendocrine tumors

T2 - A review of current knowledge

AU - Pusceddu, Sara

AU - Prinzi, Natalie

AU - Raimondi, Alessandra

AU - Corti, Francesca

AU - Buzzoni, Roberto

AU - Di Bartolomeo, Maria

AU - Seregni, Ettore

AU - Maccauro, Marco

AU - Coppa, Jorgelina

AU - Milione, Massimo

AU - Mazzaferro, Vincenzo

AU - de Braud, Filippo

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Gastroenteropancreatic neuroendocrine tumors (NETs) are a relatively rare group of heterogeneous neoplasms. The most significant advance in therapy of NETs has been the advent of the somatostatin analog octreotide, which represents a cornerstone in their management and dramatically changed the therapeutic landscape. Octreotide long-acting release (LAR) was developed to overcome some of the limitations of octreotide. Several clinical studies, including PROMID and RADIANT-2, have validated the clinical benefits of octreotide LAR in NETs, with tumor shrinkage in about 10% of patients and tumor stabilization in roughly half of cases. While the use of octreotide LAR is well-consolidated in NETs, some open questions remain. These include the use of high-dose octreotide LAR, as there is evidence that higher dose may provide longer disease control, and nonstandard treatment schedules, with administration every 21 days instead of 28 days, as well as their use in combination with targeted agents or peptide receptor radiotherapy in clinical practice. After 3 decades of clinical experience with octreotide LAR, the drug has a well-established safety profile. It is well-tolerated and treatment discontinuations due to adverse events are uncommon. One exception is cholelithiasis, which may increase with longer duration of treatment. According to the literature data, octreotide LAR is currently recommended in both functioning and nonfunctioning advanced NETs. This review summarizes the available clinical data with octreotide LAR and also provides future perspectives on its possible uses in patients with NETs.

AB - Gastroenteropancreatic neuroendocrine tumors (NETs) are a relatively rare group of heterogeneous neoplasms. The most significant advance in therapy of NETs has been the advent of the somatostatin analog octreotide, which represents a cornerstone in their management and dramatically changed the therapeutic landscape. Octreotide long-acting release (LAR) was developed to overcome some of the limitations of octreotide. Several clinical studies, including PROMID and RADIANT-2, have validated the clinical benefits of octreotide LAR in NETs, with tumor shrinkage in about 10% of patients and tumor stabilization in roughly half of cases. While the use of octreotide LAR is well-consolidated in NETs, some open questions remain. These include the use of high-dose octreotide LAR, as there is evidence that higher dose may provide longer disease control, and nonstandard treatment schedules, with administration every 21 days instead of 28 days, as well as their use in combination with targeted agents or peptide receptor radiotherapy in clinical practice. After 3 decades of clinical experience with octreotide LAR, the drug has a well-established safety profile. It is well-tolerated and treatment discontinuations due to adverse events are uncommon. One exception is cholelithiasis, which may increase with longer duration of treatment. According to the literature data, octreotide LAR is currently recommended in both functioning and nonfunctioning advanced NETs. This review summarizes the available clinical data with octreotide LAR and also provides future perspectives on its possible uses in patients with NETs.

KW - carcinoid tumors

KW - Gastroenteropancreatic neuroendocrine tumors

KW - octreotide LAR

KW - somatostatin analogs

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85064562819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064562819&partnerID=8YFLogxK

U2 - 10.1177/0300891618765362

DO - 10.1177/0300891618765362

M3 - Review article

C2 - 29714658

AN - SCOPUS:85064562819

VL - 105

SP - 113

EP - 120

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -